Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Sees Significant Growth in Short Interest

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totaling 18,047 shares, a growth of 100.7% from the December 15th total of 8,994 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily trading volume, of 107,685 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 107,685 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.3% of the shares of the stock are sold short.

Chemomab Therapeutics Stock Performance

Chemomab Therapeutics stock traded up $0.03 during trading hours on Friday, hitting $1.73. The company had a trading volume of 31,059 shares, compared to its average volume of 57,400. The firm has a market cap of $10.62 million, a P/E ratio of -0.58 and a beta of 0.51. The company has a 50-day moving average price of $2.21 and a two-hundred day moving average price of $3.07. Chemomab Therapeutics has a 1 year low of $1.60 and a 1 year high of $8.80.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CMMB shares. Zacks Research cut Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 11th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Chemomab Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $26.50.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.